Second-generation antipsychotics are serotonin-dopamine antagonists and are also known as atypical antipsychotics.
The global market for Long-Acting Schizophrenia Drug is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Long-Acting Schizophrenia Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Long-Acting Schizophrenia Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Long-Acting Schizophrenia Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Long-Acting Schizophrenia Drug market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Long-Acting Schizophrenia Drug players cover Johnson & Johnson, Teva, Eli Lilly, Bristol Myers Squibb and AstraZeneca, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Long-Acting Schizophrenia Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Long-Acting Schizophrenia Drug market, with both quantitative and qualitative data, to help readers understand how the Long-Acting Schizophrenia Drug market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.
Market Segmentation:
The study segments the Long-Acting Schizophrenia Drug market and forecasts the market size by Type (Oral and Injection,), by Application (Hospital, Pharmacies and Other,), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Oral
Injection
Segmentation by application
Hospital
Pharmacies
Other
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Johnson & Johnson
Teva
Eli Lilly
Bristol Myers Squibb
AstraZeneca
Sumitomo Dainippon Pharma
Allergan
Novartis
Cardinal Health
Sun Pharmaceutical Industries
GlaxoSmithKline
Sanis Health
Qilu Pharmaceutical
Otsuka Pharmaceutical
Vanda Pharmaceuticals
H.Lundbeck
Organon
Hansoh
Hengrui
Nhwa Group
Yangtze River Pharmaceutical Group
Chapter Introduction
Chapter 1: Scope of Long-Acting Schizophrenia Drug, Research Methodology, etc.
Chapter 2: Executive Summary, global Long-Acting Schizophrenia Drug market size and CAGR, Long-Acting Schizophrenia Drug market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Long-Acting Schizophrenia Drug revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Long-Acting Schizophrenia Drug revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Long-Acting Schizophrenia Drug market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Johnson & Johnson, Teva, Eli Lilly, Bristol Myers Squibb, AstraZeneca, Sumitomo Dainippon Pharma, Allergan, Novartis and Cardinal Health, etc.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Long-Acting Schizophrenia Drug Market Size 2017-2028
2.1.2 Long-Acting Schizophrenia Drug Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Long-Acting Schizophrenia Drug Segment by Type
2.2.1 Oral
2.2.2 Injection
2.3 Long-Acting Schizophrenia Drug Market Size by Type
2.3.1 Long-Acting Schizophrenia Drug Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Long-Acting Schizophrenia Drug Market Size Market Share by Type (2017-2022)
2.4 Long-Acting Schizophrenia Drug Segment by Application
2.4.1 Hospital
2.4.2 Pharmacies
2.4.3 Other
2.5 Long-Acting Schizophrenia Drug Market Size by Application
2.5.1 Long-Acting Schizophrenia Drug Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Long-Acting Schizophrenia Drug Market Size Market Share by Application (2017-2022)
3 Long-Acting Schizophrenia Drug Market Size by Player
3.1 Long-Acting Schizophrenia Drug Market Size Market Share by Players
3.1.1 Global Long-Acting Schizophrenia Drug Revenue by Players (2020-2022)
3.1.2 Global Long-Acting Schizophrenia Drug Revenue Market Share by Players (2020-2022)
3.2 Global Long-Acting Schizophrenia Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Long-Acting Schizophrenia Drug by Regions
4.1 Long-Acting Schizophrenia Drug Market Size by Regions (2017-2022)
4.2 Americas Long-Acting Schizophrenia Drug Market Size Growth (2017-2022)
4.3 APAC Long-Acting Schizophrenia Drug Market Size Growth (2017-2022)
4.4 Europe Long-Acting Schizophrenia Drug Market Size Growth (2017-2022)
4.5 Middle East & Africa Long-Acting Schizophrenia Drug Market Size Growth (2017-2022)
5 Americas
5.1 Americas Long-Acting Schizophrenia Drug Market Size by Country (2017-2022)
5.2 Americas Long-Acting Schizophrenia Drug Market Size by Type (2017-2022)
5.3 Americas Long-Acting Schizophrenia Drug Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Long-Acting Schizophrenia Drug Market Size by Region (2017-2022)
6.2 APAC Long-Acting Schizophrenia Drug Market Size by Type (2017-2022)
6.3 APAC Long-Acting Schizophrenia Drug Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Long-Acting Schizophrenia Drug by Country (2017-2022)
7.2 Europe Long-Acting Schizophrenia Drug Market Size by Type (2017-2022)
7.3 Europe Long-Acting Schizophrenia Drug Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Long-Acting Schizophrenia Drug by Region (2017-2022)
8.2 Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Type (2017-2022)
8.3 Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Long-Acting Schizophrenia Drug Market Forecast
10.1 Global Long-Acting Schizophrenia Drug Forecast by Regions (2023-2028)
10.1.1 Global Long-Acting Schizophrenia Drug Forecast by Regions (2023-2028)
10.1.2 Americas Long-Acting Schizophrenia Drug Forecast
10.1.3 APAC Long-Acting Schizophrenia Drug Forecast
10.1.4 Europe Long-Acting Schizophrenia Drug Forecast
10.1.5 Middle East & Africa Long-Acting Schizophrenia Drug Forecast
10.2 Americas Long-Acting Schizophrenia Drug Forecast by Country (2023-2028)
10.2.1 United States Long-Acting Schizophrenia Drug Market Forecast
10.2.2 Canada Long-Acting Schizophrenia Drug Market Forecast
10.2.3 Mexico Long-Acting Schizophrenia Drug Market Forecast
10.2.4 Brazil Long-Acting Schizophrenia Drug Market Forecast
10.3 APAC Long-Acting Schizophrenia Drug Forecast by Region (2023-2028)
10.3.1 China Long-Acting Schizophrenia Drug Market Forecast
10.3.2 Japan Long-Acting Schizophrenia Drug Market Forecast
10.3.3 Korea Long-Acting Schizophrenia Drug Market Forecast
10.3.4 Southeast Asia Long-Acting Schizophrenia Drug Market Forecast
10.3.5 India Long-Acting Schizophrenia Drug Market Forecast
10.3.6 Australia Long-Acting Schizophrenia Drug Market Forecast
10.4 Europe Long-Acting Schizophrenia Drug Forecast by Country (2023-2028)
10.4.1 Germany Long-Acting Schizophrenia Drug Market Forecast
10.4.2 France Long-Acting Schizophrenia Drug Market Forecast
10.4.3 UK Long-Acting Schizophrenia Drug Market Forecast
10.4.4 Italy Long-Acting Schizophrenia Drug Market Forecast
10.4.5 Russia Long-Acting Schizophrenia Drug Market Forecast
10.5 Middle East & Africa Long-Acting Schizophrenia Drug Forecast by Region (2023-2028)
10.5.1 Egypt Long-Acting Schizophrenia Drug Market Forecast
10.5.2 South Africa Long-Acting Schizophrenia Drug Market Forecast
10.5.3 Israel Long-Acting Schizophrenia Drug Market Forecast
10.5.4 Turkey Long-Acting Schizophrenia Drug Market Forecast
10.5.5 GCC Countries Long-Acting Schizophrenia Drug Market Forecast
10.6 Global Long-Acting Schizophrenia Drug Forecast by Type (2023-2028)
10.7 Global Long-Acting Schizophrenia Drug Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Information
11.1.2 Johnson & Johnson Long-Acting Schizophrenia Drug Product Offered
11.1.3 Johnson & Johnson Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Johnson & Johnson Main Business Overview
11.1.5 Johnson & Johnson Latest Developments
11.2 Teva
11.2.1 Teva Company Information
11.2.2 Teva Long-Acting Schizophrenia Drug Product Offered
11.2.3 Teva Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Teva Main Business Overview
11.2.5 Teva Latest Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Company Information
11.3.2 Eli Lilly Long-Acting Schizophrenia Drug Product Offered
11.3.3 Eli Lilly Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Eli Lilly Main Business Overview
11.3.5 Eli Lilly Latest Developments
11.4 Bristol Myers Squibb
11.4.1 Bristol Myers Squibb Company Information
11.4.2 Bristol Myers Squibb Long-Acting Schizophrenia Drug Product Offered
11.4.3 Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Bristol Myers Squibb Main Business Overview
11.4.5 Bristol Myers Squibb Latest Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca Long-Acting Schizophrenia Drug Product Offered
11.5.3 AstraZeneca Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 AstraZeneca Main Business Overview
11.5.5 AstraZeneca Latest Developments
11.6 Sumitomo Dainippon Pharma
11.6.1 Sumitomo Dainippon Pharma Company Information
11.6.2 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Product Offered
11.6.3 Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.6.4 Sumitomo Dainippon Pharma Main Business Overview
11.6.5 Sumitomo Dainippon Pharma Latest Developments
11.7 Allergan
11.7.1 Allergan Company Information
11.7.2 Allergan Long-Acting Schizophrenia Drug Product Offered
11.7.3 Allergan Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.7.4 Allergan Main Business Overview
11.7.5 Allergan Latest Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis Long-Acting Schizophrenia Drug Product Offered
11.8.3 Novartis Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.8.4 Novartis Main Business Overview
11.8.5 Novartis Latest Developments
11.9 Cardinal Health
11.9.1 Cardinal Health Company Information
11.9.2 Cardinal Health Long-Acting Schizophrenia Drug Product Offered
11.9.3 Cardinal Health Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.9.4 Cardinal Health Main Business Overview
11.9.5 Cardinal Health Latest Developments
11.10 Sun Pharmaceutical Industries
11.10.1 Sun Pharmaceutical Industries Company Information
11.10.2 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Product Offered
11.10.3 Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.10.4 Sun Pharmaceutical Industries Main Business Overview
11.10.5 Sun Pharmaceutical Industries Latest Developments
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Information
11.11.2 GlaxoSmithKline Long-Acting Schizophrenia Drug Product Offered
11.11.3 GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.11.4 GlaxoSmithKline Main Business Overview
11.11.5 GlaxoSmithKline Latest Developments
11.12 Sanis Health
11.12.1 Sanis Health Company Information
11.12.2 Sanis Health Long-Acting Schizophrenia Drug Product Offered
11.12.3 Sanis Health Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.12.4 Sanis Health Main Business Overview
11.12.5 Sanis Health Latest Developments
11.13 Qilu Pharmaceutical
11.13.1 Qilu Pharmaceutical Company Information
11.13.2 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Product Offered
11.13.3 Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.13.4 Qilu Pharmaceutical Main Business Overview
11.13.5 Qilu Pharmaceutical Latest Developments
11.14 Otsuka Pharmaceutical
11.14.1 Otsuka Pharmaceutical Company Information
11.14.2 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Product Offered
11.14.3 Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.14.4 Otsuka Pharmaceutical Main Business Overview
11.14.5 Otsuka Pharmaceutical Latest Developments
11.15 Vanda Pharmaceuticals
11.15.1 Vanda Pharmaceuticals Company Information
11.15.2 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Product Offered
11.15.3 Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.15.4 Vanda Pharmaceuticals Main Business Overview
11.15.5 Vanda Pharmaceuticals Latest Developments
11.16 H.Lundbeck
11.16.1 H.Lundbeck Company Information
11.16.2 H.Lundbeck Long-Acting Schizophrenia Drug Product Offered
11.16.3 H.Lundbeck Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.16.4 H.Lundbeck Main Business Overview
11.16.5 H.Lundbeck Latest Developments
11.17 Organon
11.17.1 Organon Company Information
11.17.2 Organon Long-Acting Schizophrenia Drug Product Offered
11.17.3 Organon Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.17.4 Organon Main Business Overview
11.17.5 Organon Latest Developments
11.18 Hansoh
11.18.1 Hansoh Company Information
11.18.2 Hansoh Long-Acting Schizophrenia Drug Product Offered
11.18.3 Hansoh Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.18.4 Hansoh Main Business Overview
11.18.5 Hansoh Latest Developments
11.19 Hengrui
11.19.1 Hengrui Company Information
11.19.2 Hengrui Long-Acting Schizophrenia Drug Product Offered
11.19.3 Hengrui Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.19.4 Hengrui Main Business Overview
11.19.5 Hengrui Latest Developments
11.20 Nhwa Group
11.20.1 Nhwa Group Company Information
11.20.2 Nhwa Group Long-Acting Schizophrenia Drug Product Offered
11.20.3 Nhwa Group Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.20.4 Nhwa Group Main Business Overview
11.20.5 Nhwa Group Latest Developments
11.21 Yangtze River Pharmaceutical Group
11.21.1 Yangtze River Pharmaceutical Group Company Information
11.21.2 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Product Offered
11.21.3 Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue, Gross Margin and Market Share (2020-2022)
11.21.4 Yangtze River Pharmaceutical Group Main Business Overview
11.21.5 Yangtze River Pharmaceutical Group Latest Developments
12 Research Findings and Conclusion
List of Tables
Table 1. Long-Acting Schizophrenia Drug Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Oral
Table 3. Major Players of Injection
Table 4. Long-Acting Schizophrenia Drug Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 5. Global Long-Acting Schizophrenia Drug Market Size by Type (2017-2022) & ($ Millions)
Table 6. Global Long-Acting Schizophrenia Drug Market Size Market Share by Type (2017-2022)
Table 7. Long-Acting Schizophrenia Drug Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 8. Global Long-Acting Schizophrenia Drug Market Size by Application (2017-2022) & ($ Millions)
Table 9. Global Long-Acting Schizophrenia Drug Market Size Market Share by Application (2017-2022)
Table 10. Global Long-Acting Schizophrenia Drug Revenue by Players (2020-2022) & ($ Millions)
Table 11. Global Long-Acting Schizophrenia Drug Revenue Market Share by Player (2020-2022)
Table 12. Long-Acting Schizophrenia Drug Key Players Head office and Products Offered
Table 13. Long-Acting Schizophrenia Drug Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Long-Acting Schizophrenia Drug Market Size by Regions 2017-2022 & ($ Millions)
Table 17. Global Long-Acting Schizophrenia Drug Market Size Market Share by Regions (2017-2022)
Table 18. Americas Long-Acting Schizophrenia Drug Market Size by Country (2017-2022) & ($ Millions)
Table 19. Americas Long-Acting Schizophrenia Drug Market Size Market Share by Country (2017-2022)
Table 20. Americas Long-Acting Schizophrenia Drug Market Size by Type (2017-2022) & ($ Millions)
Table 21. Americas Long-Acting Schizophrenia Drug Market Size Market Share by Type (2017-2022)
Table 22. Americas Long-Acting Schizophrenia Drug Market Size by Application (2017-2022) & ($ Millions)
Table 23. Americas Long-Acting Schizophrenia Drug Market Size Market Share by Application (2017-2022)
Table 24. APAC Long-Acting Schizophrenia Drug Market Size by Region (2017-2022) & ($ Millions)
Table 25. APAC Long-Acting Schizophrenia Drug Market Size Market Share by Region (2017-2022)
Table 26. APAC Long-Acting Schizophrenia Drug Market Size by Type (2017-2022) & ($ Millions)
Table 27. APAC Long-Acting Schizophrenia Drug Market Size Market Share by Type (2017-2022)
Table 28. APAC Long-Acting Schizophrenia Drug Market Size by Application (2017-2022) & ($ Millions)
Table 29. APAC Long-Acting Schizophrenia Drug Market Size Market Share by Application (2017-2022)
Table 30. Europe Long-Acting Schizophrenia Drug Market Size by Country (2017-2022) & ($ Millions)
Table 31. Europe Long-Acting Schizophrenia Drug Market Size Market Share by Country (2017-2022)
Table 32. Europe Long-Acting Schizophrenia Drug Market Size by Type (2017-2022) & ($ Millions)
Table 33. Europe Long-Acting Schizophrenia Drug Market Size Market Share by Type (2017-2022)
Table 34. Europe Long-Acting Schizophrenia Drug Market Size by Application (2017-2022) & ($ Millions)
Table 35. Europe Long-Acting Schizophrenia Drug Market Size Market Share by Application (2017-2022)
Table 36. Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Region (2017-2022) & ($ Millions)
Table 37. Middle East & Africa Long-Acting Schizophrenia Drug Market Size Market Share by Region (2017-2022)
Table 38. Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Type (2017-2022) & ($ Millions)
Table 39. Middle East & Africa Long-Acting Schizophrenia Drug Market Size Market Share by Type (2017-2022)
Table 40. Middle East & Africa Long-Acting Schizophrenia Drug Market Size by Application (2017-2022) & ($ Millions)
Table 41. Middle East & Africa Long-Acting Schizophrenia Drug Market Size Market Share by Application (2017-2022)
Table 42. Key Market Drivers & Growth Opportunities of Long-Acting Schizophrenia Drug
Table 43. Key Market Challenges & Risks of Long-Acting Schizophrenia Drug
Table 44. Key Industry Trends of Long-Acting Schizophrenia Drug
Table 45. Global Long-Acting Schizophrenia Drug Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 46. Global Long-Acting Schizophrenia Drug Market Size Market Share Forecast by Regions (2023-2028)
Table 47. Global Long-Acting Schizophrenia Drug Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 48. Global Long-Acting Schizophrenia Drug Market Size Market Share Forecast by Type (2023-2028)
Table 49. Global Long-Acting Schizophrenia Drug Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 50. Global Long-Acting Schizophrenia Drug Market Size Market Share Forecast by Application (2023-2028)
Table 51. Johnson & Johnson Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 52. Johnson & Johnson Long-Acting Schizophrenia Drug Product Offered
Table 53. Johnson & Johnson Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 54. Johnson & Johnson Main Business
Table 55. Johnson & Johnson Latest Developments
Table 56. Teva Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 57. Teva Long-Acting Schizophrenia Drug Product Offered
Table 58. Teva Main Business
Table 59. Teva Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 60. Teva Latest Developments
Table 61. Eli Lilly Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 62. Eli Lilly Long-Acting Schizophrenia Drug Product Offered
Table 63. Eli Lilly Main Business
Table 64. Eli Lilly Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 65. Eli Lilly Latest Developments
Table 66. Bristol Myers Squibb Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 67. Bristol Myers Squibb Long-Acting Schizophrenia Drug Product Offered
Table 68. Bristol Myers Squibb Main Business
Table 69. Bristol Myers Squibb Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 70. Bristol Myers Squibb Latest Developments
Table 71. AstraZeneca Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 72. AstraZeneca Long-Acting Schizophrenia Drug Product Offered
Table 73. AstraZeneca Main Business
Table 74. AstraZeneca Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 75. AstraZeneca Latest Developments
Table 76. Sumitomo Dainippon Pharma Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 77. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Product Offered
Table 78. Sumitomo Dainippon Pharma Main Business
Table 79. Sumitomo Dainippon Pharma Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 80. Sumitomo Dainippon Pharma Latest Developments
Table 81. Allergan Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 82. Allergan Long-Acting Schizophrenia Drug Product Offered
Table 83. Allergan Main Business
Table 84. Allergan Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 85. Allergan Latest Developments
Table 86. Novartis Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 87. Novartis Long-Acting Schizophrenia Drug Product Offered
Table 88. Novartis Main Business
Table 89. Novartis Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 90. Novartis Latest Developments
Table 91. Cardinal Health Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 92. Cardinal Health Long-Acting Schizophrenia Drug Product Offered
Table 93. Cardinal Health Main Business
Table 94. Cardinal Health Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 95. Cardinal Health Latest Developments
Table 96. Sun Pharmaceutical Industries Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 97. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Product Offered
Table 98. Sun Pharmaceutical Industries Main Business
Table 99. Sun Pharmaceutical Industries Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 100. Sun Pharmaceutical Industries Latest Developments
Table 101. GlaxoSmithKline Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 102. GlaxoSmithKline Long-Acting Schizophrenia Drug Product Offered
Table 103. GlaxoSmithKline Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 104. GlaxoSmithKline Main Business
Table 105. GlaxoSmithKline Latest Developments
Table 106. Sanis Health Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 107. Sanis Health Long-Acting Schizophrenia Drug Product Offered
Table 108. Sanis Health Main Business
Table 109. Sanis Health Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 110. Sanis Health Latest Developments
Table 111. Qilu Pharmaceutical Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 112. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Product Offered
Table 113. Qilu Pharmaceutical Main Business
Table 114. Qilu Pharmaceutical Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 115. Qilu Pharmaceutical Latest Developments
Table 116. Otsuka Pharmaceutical Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 117. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Product Offered
Table 118. Otsuka Pharmaceutical Main Business
Table 119. Otsuka Pharmaceutical Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 120. Otsuka Pharmaceutical Latest Developments
Table 121. Vanda Pharmaceuticals Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 122. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Product Offered
Table 123. Vanda Pharmaceuticals Main Business
Table 124. Vanda Pharmaceuticals Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 125. Vanda Pharmaceuticals Latest Developments
Table 126. H.Lundbeck Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 127. H.Lundbeck Long-Acting Schizophrenia Drug Product Offered
Table 128. H.Lundbeck Main Business
Table 129. H.Lundbeck Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 130. H.Lundbeck Latest Developments
Table 131. Organon Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 132. Organon Long-Acting Schizophrenia Drug Product Offered
Table 133. Organon Main Business
Table 134. Organon Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 135. Organon Latest Developments
Table 136. Hansoh Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 137. Hansoh Long-Acting Schizophrenia Drug Product Offered
Table 138. Hansoh Main Business
Table 139. Hansoh Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 140. Hansoh Latest Developments
Table 141. Hengrui Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 142. Hengrui Long-Acting Schizophrenia Drug Product Offered
Table 143. Hengrui Main Business
Table 144. Hengrui Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 145. Hengrui Latest Developments
Table 146. Nhwa Group Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 147. Nhwa Group Long-Acting Schizophrenia Drug Product Offered
Table 148. Nhwa Group Main Business
Table 149. Nhwa Group Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 150. Nhwa Group Latest Developments
Table 151. Yangtze River Pharmaceutical Group Details, Company Type, Long-Acting Schizophrenia Drug Area Served and Its Competitors
Table 152. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Product Offered
Table 153. Yangtze River Pharmaceutical Group Long-Acting Schizophrenia Drug Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 154. Yangtze River Pharmaceutical Group Main Business
Table 155. Yangtze River Pharmaceutical Group Latest Developments
List of Figures
List of Figures
Figure 1. Long-Acting Schizophrenia Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Long-Acting Schizophrenia Drug Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Long-Acting Schizophrenia Drug Market Size Market Share by Type in 2021
Figure 7. Long-Acting Schizophrenia Drug in Hospital
Figure 8. Global Long-Acting Schizophrenia Drug Market: Hospital (2017-2022) & ($ Millions)
Figure 9. Long-Acting Schizophrenia Drug in Pharmacies
Figure 10. Global Long-Acting Schizophrenia Drug Market: Pharmacies (2017-2022) & ($ Millions)
Figure 11. Long-Acting Schizophrenia Drug in Other
Figure 12. Global Long-Acting Schizophrenia Drug Market: Other (2017-2022) & ($ Millions)
Figure 13. Global Long-Acting Schizophrenia Drug Market Size Market Share by Application in 2021
Figure 14. Global Long-Acting Schizophrenia Drug Revenue Market Share by Player in 2021
Figure 15. Global Long-Acting Schizophrenia Drug Market Size Market Share by Regions (2017-2022)
Figure 16. Americas Long-Acting Schizophrenia Drug Market Size 2017-2022 ($ Millions)
Figure 17. APAC Long-Acting Schizophrenia Drug Market Size 2017-2022 ($ Millions)
Figure 18. Europe Long-Acting Schizophrenia Drug Market Size 2017-2022 ($ Millions)
Figure 19. Middle East & Africa Long-Acting Schizophrenia Drug Market Size 2017-2022 ($ Millions)
Figure 20. Americas Long-Acting Schizophrenia Drug Value Market Share by Country in 2021
Figure 21. Americas Long-Acting Schizophrenia Drug Consumption Market Share by Type in 2021
Figure 22. Americas Long-Acting Schizophrenia Drug Market Size Market Share by Application in 2021
Figure 23. United States Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 24. Canada Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 25. Mexico Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 26. Brazil Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 27. APAC Long-Acting Schizophrenia Drug Market Size Market Share by Region in 2021
Figure 28. APAC Long-Acting Schizophrenia Drug Market Size Market Share by Application in 2021
Figure 29. China Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 30. Japan Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 31. Korea Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 32. Southeast Asia Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 33. India Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 34. Australia Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 35. Europe Long-Acting Schizophrenia Drug Market Size Market Share by Country in 2021
Figure 36. Europe Long-Acting Schizophrenia Drug Market Size Market Share by Type in 2021
Figure 37. Europe Long-Acting Schizophrenia Drug Market Size Market Share by Application in 2021
Figure 38. Germany Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 39. France Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 40. UK Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 41. Italy Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 42. Russia Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 43. Middle East & Africa Long-Acting Schizophrenia Drug Market Size Market Share by Region in 2021
Figure 44. Middle East & Africa Long-Acting Schizophrenia Drug Market Size Market Share by Type in 2021
Figure 45. Middle East & Africa Long-Acting Schizophrenia Drug Market Size Market Share by Application in 2021
Figure 46. Egypt Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 47. South Africa Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 48. Israel Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 49. Turkey Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 50. GCC Country Long-Acting Schizophrenia Drug Market Size Growth 2017-2022 ($ Millions)
Figure 51. Americas Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 52. APAC Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 53. Europe Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 54. Middle East & Africa Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 55. United States Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 56. Canada Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 57. Mexico Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 58. Brazil Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 59. China Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 60. Japan Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 61. Korea Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 62. Southeast Asia Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 63. India Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 64. Australia Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 65. Germany Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 66. France Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 67. UK Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 68. Italy Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 69. Russia Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 70. Spain Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 71. Egypt Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 72. South Africa Long-Acting Schizophrenia Drug Market Size 2023-2028 ($ Millions)
Figure 73. Israel Long-Acting Schizophrenia Drug Market Size 2023-2028
Global Freckle-removing Medical and Beau..
The global market for Freckle-removing Medical and Beauty Eq..
+16467917070US (Toll Free)